AndreaBozzo/ceres-open-data-index huggingface dataset:
SERN Reliability: Indicators Contributing to Risk and Needs Ratings

In 2019, the Romanian Probation Service (RPS) nationally implemented a ‘Scale for the Evaluation of Risk and Needs’ (or SERN) that was modeled earlier on the static and dynamic factors components of Correctional Service of Canada’s (CSC) Offender Intake Assessment process. This project continues the technical assistance being provided under the auspices of a 2022 joint statement of cooperation between the Probation Directorate of Romania and CSC. The present study explores the reliability of the SERN or the extent to which its items are consistent with an overall 5-level risk and needs rating. 


Organization: Correctional Service of Canada | Service correctionnel du Canada
Welcome binder for Associate Deputy Minister of Employment and Social Development and Chief Operating Officer for Service Canada Cliff Groen – 2024

Employment and Social Development Canada departmental overview
The ESDC portfolio - Mission
Employment and Social Development Canada's core responsibilities
How we carry out ESDC's mandate
Legislative framework
Organizational structure
Biographies of deputy ministers
Commissions, Tribunals, Councils and Committees
Annex A
Service Canada Overview
Infographics
Service Canada 101
Service Canada Organizational Structure Overview
Service Canada Regions
Key Internal Documents (Human Resources Services Branch (HRSB), Chief Financial Officer Branch (CFOB), SSPB, Audit)
HR Overview
Financial Overview
Departmental Corporate Risks, Including Service Delivery Risks
Audit and Evaluation Forward Agenda and Considerations
Forward Agenda Performance Measurement and Evaluation Committee Agendas
Public Documents (SSPB)

Organization: Employment and Social Development Canada | Emploi et Développement social Canada
A Profile of Offenders Unlawfully at Large

Unlawfully at large offenders are a higher risk and higher need group with more problematic institutional behaviour compared to non-UAL offenders. Conditional release to the community is an important strategy for offender management in order to support their reintegration. Offenders unlawfully at large (UAL) present a challenge for correctional jurisdictions; however, there is limited research examining this population.


Organization: Correctional Service of Canada | Service correctionnel du Canada
Post-pandemic Provisional Federal Community Status Forecasts

Over the course of two recent fiscal years (2020 to 2021 and 2021 to 2022), marked by the COVID-19 pandemic era, the Correctional Service of Canada (CSC) experienced an unprecedented decline in the federal community supervision (-903 or 9.6%) population. Consequently, a pause occurred in the annual forecasting exercise. Then, in 2022 new 10-year community supervision population projections were estimated to fiscal year-end 2031 to 2032.


Organization: Correctional Service of Canada | Service correctionnel du Canada
Experiences at Prince Albert Grand Council Spiritual Healing Lodge

Prince Albert Grand Council Spritual Healing Lodge (PAGC) offers a culturally focused approach to healing and gradual reintegration for Indigenous residents. Prince Albert Grand Council (PAGC) Spiritual Healing Lodge is a men’s Section 81 facility located in Prince Albert, Saskatchewan. The goal of the current study is to better understand perceptions of PAGC Healing Lodge, as well as the challenges that are currently facing the operation of the site. 


Organization: Correctional Service of Canada | Service correctionnel du Canada
Prevalence of SARS-CoV-2 Antibodies among Federally Incarcerated Women

In collaboration with Public Health Agency of Canada (PHAC) and the University of Ottawa, Correctional Service Canada (CSC) conducted the 2022 National Health Survey. One of the study objectives was to determine the prevalence of SARS-CoV-2 antibodies and whether they are derived from immunization or infection among federally incarcerated women.


Organization: Correctional Service of Canada | Service correctionnel du Canada
Serology results and self-reported diagnosis concordance: HIV, HCV, and Syphilis

In collaboration with Public Health Agency of Canada (PHAC) and the University of Ottawa, Correctional Service Canada (CSC) conducted the 2022 National Health Survey. One study objective was to determine the number and proportion of people in federal prisons living with Human Immunodeficiency virus (HIV), Hepatitis C virus (HCV), and syphilis who are aware of their infection. 


Organization: Correctional Service of Canada | Service correctionnel du Canada
Offenders Currently Unlawfully at Large

Unlawfully at large (UAL) offenders were a high risk and need group, with violent offence convictions and incidents involving an escape. Conditional release to the community is an important strategy for offender management in order to support their reintegration. Offenders unlawfully at large (UAL) present a challenge for correctional jurisdictions; however, there is limited research examining this population. 


Organization: Correctional Service of Canada | Service correctionnel du Canada
Prevalence of SARS-CoV-2 Antibodies among Federally Incarcerated Men

In collaboration with Public Health Agency of Canada (PHAC) and the University of Ottawa, Correctional Service Canada (CSC) conducted the 2022 National Health Survey. One of the study objectives was to determine the prevalence of SARS-CoV-2 antibodies and whether they are derived from immunization or infection among federally incarcerated men. 


Organization: Correctional Service of Canada | Service correctionnel du Canada
Canada Mortgage and Housing Corporation, housing starts in all centres 10,000 and over, Canada, provinces, and census metropolitan areas, seasonally adjusted at annual rates, quarterly

This table contains data described by the following dimensions (Not all combinations are available): Geography (47 items: Canada; Prince Edward Island; Atlantic provinces; Newfoundland and Labrador ...), Type of unit (6 items: Total units; Multiples; Semi-detached units; Single-detached units ...).	


Organization: Canada Mortgage and Housing Corporation | Société canadienne d'hypothèques et de logement
Canada Mortgage and Housing Corporation, newly completed and unoccupied housing in selected census metropolitan areas and census agglomerations of 50,000 and over

This table contains data described by the following dimensions (Not all combinations are available): Geography (67 items: Barrie; Ontario; Abbotsford-Mission; British Columbia; Census metropolitan areas and census agglomerations of 50,000 and over; Census metropolitan areas ...), Type of unit (7 items: Total units; Single-detached and semi-detached units; Semi-detached units; Single-detached units ...).


Organization: Canada Mortgage and Housing Corporation | Société canadienne d'hypothèques et de logement
Canada Mortgage and Housing Corporation, housing starts, all rural areas, Canada and provinces, seasonally adjusted at annual rates, quarterly

This table contains data described by the following dimensions (Not all combinations are available): Geography (13 items: Newfoundland and Labrador; Prince Edward Island; Atlantic provinces; Canada ...), Type of unit (3 items: Total units; Multiples; Single-detached units ...).


Organization: Canada Mortgage and Housing Corporation | Société canadienne d'hypothèques et de logement
Canada Mortgage and Housing Corporation, housing starts, all areas, Canada and provinces, seasonally adjusted at annual rates, quarterly

This table contains data described by the following dimensions (Not all combinations are available): Geography (13 items: Canada; Prince Edward Island; Atlantic provinces; Newfoundland and Labrador ...), Type of unit (3 items: Total units; Multiples; Single-detached units ...).


Organization: Canada Mortgage and Housing Corporation | Société canadienne d'hypothèques et de logement
Summary Safety Review - Proton Pump Inhibitors - Assessing the Potential Risk of Clostridium difficile Infection

This safety review was carried out to look at new information in the scientific literature that has emerged since the completion of a previous review in 2012 about the risk of Clostridium difficile infection with proton pump inhibitor use. Clostridium difficile infection ranges from mild diarrhea to life-threatening multi-organ failure, especially in elderly patients with other pre-existing conditions. 

Organization: Health Canada | Santé Canada
Summary Safety Review - Proton Pump Inhibitors (PPIs) - Assessing the risk of a type of skin reaction [Subacute Cutaneous Lupus Erythematosus (SCLE)]

Health Canada reviewed the potential risk of a type of skin reaction known as subacute cutaneous lupus erythematosus(SCLE) with the use of PPIs after a published article that found these drugs may contribute to the reaction.

Organization: Health Canada | Santé Canada
Summary Safety Review - SGLT2 inhibitors - Assessing the potential risk of a rare brain condition (posterior reversible encephalopathy syndrome) in patients who have developed high levels of acids in the blood (diabetic ketoacidosis)  

After receiving two Canadian case reports involving canagliflozin, Health Canada reviewed the potential risk of PRES in patients treated with SGLT2 inhibitors who have developed DKA. SGLT2 inhibitors have been linked to an increased risk of DKA, which is a serious complication of diabetes. Posterior reversible encephalopathy syndrome is a rare condition which can affect the brain and is characterized by sudden changes in the nervous system including headaches, confusion, seizures, and vision trouble. It can develop in association with many conditions, such as severe infection or DKA, and drugs. When PRES is caused by a drug, it is important to stop the use of the drug as soon as possible to avoid complications.

Organization: Health Canada | Santé Canada
Summary Safety Review - SGLT2 Inhibitors (canagliflozin, dapagliflozin, empagliflozin) - Assessing the Potential Risk of Bone-Related Side Effects

The minerals stored within the bones help provide strength. Bones that have fewer minerals (less bone mineral density) are more likely to become brittle and break (fracture). A safety review was carried out by Health Canada to evaluate the risk of bone-related side effects of using SGLT2 inhibitors. The review was triggered by a notice about international reports of bone-related side effects experienced in patients taking the SGLT2 inhibitor canagliflozin.

Organization: Health Canada | Santé Canada
Summary Safety Review - SGLT2 Inhibitors (canagliflozin, dapagliflozin, empagliflozin) - Assessing the Risk of the Body Producing High Levels of Acids in the Blood (diabetic ketoacidosis)

Ketones are a type of waste product that the body creates when it breaks down fat to use for energy. If ketones begin to build up to toxic levels in the blood (a condition known as diabetic ketoacidosis) it can lead to symptoms such as difficulties in breathing, stomach pain, nausea and vomiting, confusion, tiredness, loss of appetite, and excessive thirst. It can lead to a coma in extreme cases. Diabetic ketoacidosis can happen to anyone with diabetes but it is more common in those with type 1 diabetes, and quite rare in people with type 2 diabetes.

Organization: Health Canada | Santé Canada
Summary Safety Review - Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors INVOKANA (canagliflozin) and FORXIGA (dapagliflozin) - Evaluation of a Potential Risk of Acute Kidney Injury

A safety review was done to evaluate the potential risk of acute kidney injury and the use of two SGLT2 inhibitors, Invokana (canagliflozin) or Forxiga (dapagliflozin). This issue was identified following new safety information received from the manufacturer of Invokana following the marketing of this product.

Organization: Health Canada | Santé Canada
Summary Safety Review - Strontium - Risk of Heart and Circulatory Side Effects

The European Medicines Agency completed a safety review of strontium ranelate, a drug available by prescription only in Europe at a dose of 680 mg per day and used to treat osteoporosis that is considered severe due to the high risk of fracture. Analysis demonstrated that the increased risk of heart and circulatory effects was only significant in patients with a current or past history of heart and circulatory problems. Health Canada started its safety review because the risk of heart and circulatory side effects is a serious health issue, and because strontium is found in licensed natural health products as strontium salts, including strontium citrate, strontium lactate, and strontium gluconate.

Organization: Health Canada | Santé Canada
Summary Safety Review - TECFIDERA - Assessing the Potential Risk of Kidney Injury

Health Canada reviewed the risk of kidney injury with Tecfidera after finding international cases of this risk in patients treated with Tecfidera. These cases were found during routine review of information received from the manufacturer. In Canada, the product information for Tecfidera has details about possible kidney effects that were seen in animal studies, in addition to changes in urine test results seen in human studies. Based on this, monitoring of kidney function is recommended on the product information as a precaution. Potential causes of kidney injury can include not having enough fluids in the body (dehydration) resulting from nausea and vomiting, which were common in human studies with Tecfidera.

Organization: Health Canada | Santé Canada
Summary Safety Review - Topical Antiseptic Non-Prescription Chlorhexidine Products - Assessing the Potential Risk of Serious Allergic Reactions (hypersensitivity reactions)

This safety review was carried out to look at the potential link between non-prescription topical antiseptic chlorhexidine products and serious allergic reactions, and to determine if there is a need for additional labelling requirements. Symptoms of a serious allergic reaction, including anaphylaxis, may include itchy hives with swelling of the face, eyes, lips, mouth or throat; difficulty breathing; throat tightness or hoarseness; and fainting. An anaphylactic reaction is a serious and potentially life-threatening hypersensitivity reaction.

Organization: Health Canada | Santé Canada
Summary Safety Review - Tramadol-containing Products - Assessing the Potential Risk of Serious Breathing Problems (Respiratory Depression) in Children and Adolescents

The product information for tramadol warns of the risk of serious breathing problems when too much is taken. Health Canada's safety review on codeine (another opioid drug) to study the risk of serious breathing problems in children and adolescents triggered this review for tramadol. Tramadol is an opioid drug authorized in Canada for the treatment of moderate to moderately severe pain but is not recommended for use in patients under 18 years of age. However, Health Canada is aware that this drug is being used in children and adolescents (known as off-label use).

Organization: Health Canada | Santé Canada
Summary Safety Review - Trifecta Heart Valve - Assessing the Potential Risk of Early Wear

After reviewing an article about the wearing out of the Trifecta heart valve 34 months after it was implanted in a patient, Health Canada carried out a safety review of related patient reports both in Canada and internationally. When a heart valve implant does not function properly it can place stress on the heart and a patient typically has to undergo surgery or an invasive procedure to have the valve repaired or replaced.

Organization: Health Canada | Santé Canada
Summary Safety Review - ULORIC (febuxostat) - Assessing a Possible Risk of Drug Reaction/Rash with Eosinophilia and Systemic Symptoms (DRESS)

Health Canada carried out a safety review after finding international cases of DRESS suspected of being linked with the use of Uloric (febuxostat). DRESS describes a group of rare, but serious and potentially life-threatening, side effects of a medication, with symptoms such as fever, severe skin rash with swollen face or peeling of the skin over large areas of the body, etc. These reactions usually happen two weeks to two months after starting a medication.

Organization: Health Canada | Santé Canada
Summary Safety Review - Viscous Lidocaine 2% - Assessing the Potential Risk of Severe Side Effects in Infants and Young Children

Health Canada carried out a safety review to assess the potential risk of severe side effects in infants and young children with the use of viscous lidocaine. The issue was triggered after the United States Food and Drug Administration issued a safety announcement that viscous lidocaine should not be used for teething pain in infants and children. In addition, the Food and Drug Administration required that labels describe the risk of severe side effects in this age group. The severe side effects reported in the United States have not been seen in Canada, but they have been reported in the international medical literature. The current Canadian product information does not recommend the use of viscous lidocaine for teething pain in infants and young children.

Organization: Health Canada | Santé Canada
Summary Safety Review - ZOFRAN (ondansetron) - Assessing the Potential Harm to the Fetus

Health Canada carried out a safety review to assess the risk of birth defects with the use of ondansetron, as part of routine health product monitoring and because this drug is not authorized for sale in Canada to treat nausea and vomiting during pregnancy. The use of ondansetron during pregnancy is not recommended because its safety has not been established in pregnant women.

Organization: Health Canada | Santé Canada
Summary Safety Review - Phenylephrine and acetaminophen - Drug-drug interaction

Health Canada initiated a safety review following a report by the European Medicines Agency about the potential drug-drug interaction between phenylephrine and acetaminophen. These drugs are often found together in over-the-counter health products including those for treating cold, flu and allergies. People who have high blood pressure or heart disease may be more vulnerable to the side effects of phenylephrine if both of these drugs are taken together as there appears to be an interaction between them that leads to an increase of phenylephrine in the body (increased bioavailability).

Organization: Health Canada | Santé Canada
Summary Safety Review - Hydrocodone-containing products - Assessing the Risk of Serious Breathing Problems (respiratory depression) in Children and Adolescents

It is known that hydrocodone can slow breathing when too much is taken. The labelling for these drugs already warns of this risk and it applies to all ages, including children. Health Canada’s safety review activities on hydrocodone further studied the risk of serious breathing problems in children and adolescents and stems from review work with codeine (another opioid drug) to determine if more safety measures were needed.

Organization: Health Canada | Santé Canada
Summary Safety Review - GARDASIL (Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) - Assessing General Safety with a Focus on Autoimmune and Cardiovascular Diseases

The safety of all vaccines, including Gardasil, is under continuous monitoring by Health Canada and the Public Health Agency of Canada. The safety of Gardasil was reassessed as part of this monitoring and when cases of side effects after vaccination with Gardasil were reported in early 2015. These side effects included diseases where the body's own defence system attacks itself (autoimmune diseases), such as rheumatoid arthritis and multiple sclerosis, and diseases affecting the heart and blood vessels (cardiovascular diseases), such as low blood pressure and blood clots.

Organization: Health Canada | Santé Canada
Summary Safety Review - Gadolinium based contrast agents - Assessing the risk of gadolinium build-up in the brain and potential brain and nervous system (neurological) side effects

In 2016, Health Canada reviewed the risk of gadolinium build-up in the brain and potential neurological side effects in light of published studies showing that gadolinium may accumulate in the brain when GBCAs are given repeatedly. The neurological effects of these build-ups are not known.

Organization: Health Canada | Santé Canada
Summary Safety Review - Gabapentin - Assessing the Potential Risk of Serious Breathing Problems

In 2014, the product information for gabapentin products was updated to warn about the risk of serious breathing problems (respiratory depression) when it is used with an opioid. While reviewing safety information given by the manufacturer for this change, Health Canada found cases of respiratory depression in patients treated with gabapentin alone. Therefore, this current safety review was carried out to assess the possibility of the same concerns in patients using gabapentin alone (when not taken with opioids) and to find out if more safety measures were needed.

Organization: Health Canada | Santé Canada
Summary Safety Review - Fluoroquinolones - Assessing the potential risk of persistent and disabling side effects

Health Canada started a safety review following a review done by the FDA on systemic (taken by mouth or by injection) fluoroquinolone drugs. The FDA review showed that there were persistent (lasting 30 days or longer after stopping use of fluoroquinolones) and disabling side effects linked to the use of fluoroquinolone products. 

Organization: Health Canada | Santé Canada
Summary Safety Review - Finasteride - Assessing the Potential Risk of Serious Muscle-Related Side Effects

Health Canada reviewed the risk of potential serious muscle-related side effects with finasteride use because of reports in which these events were seen in patients treated with Propecia and Proscar. The safety review focussed on potential risks of serious muscle-related adverse events such as rhabdomyolysis (pain in muscles with breakdown of muscle tissue and an increase in certain muscle proteins known as creatine kinase [CK] enzymes, myopathy (disease of muscles with pain and an increase in CK enzymes) and muscle disorders such as pain, weakness, atrophy (wasting) or stiffness.

Organization: Health Canada | Santé Canada
Summary Safety Review - EYLEA (aflibercept) - Assessing the Risk of Side Effects Outside the Eye (systemic side effects)

A safety review was carried out by Health Canada to evaluate the risk of harmful side effects in areas of the body other than the eye (systemic toxicity) associated with Eylea. The review was triggered by 3 scientific studies which observed that following injection into the eye, Eylea is removed from the body's bloodstream slower than alternative products, and this could possibly lead to systemic toxicity.

Organization: Health Canada | Santé Canada
Summary Safety Review - ABILIFY and ABILIFY MAINTENA (aripiprazole) - Evaluating the Risk of Certain Impulse Control Behaviours

A safety review was conducted to evaluate the potential link between Abilify and Abilify Maintena (aripiprazole) and certain behaviours where individuals cannot control their urges (impulse control behaviours): uncontrollable gambling (pathological gambling) and sexual behaviours (hypersexuality).

Organization: Health Canada | Santé Canada
Summary Safety Review - Alpha Lipoic Acid - Assessing the Potential Risk of Low Blood Sugar (Hypoglycemic Episodes)

This safety review was carried out by Health Canada after the publication of case reports of IAS (insulin autoimmune syndrome) causing hypoglycemic episodes linked with the use of oral alpha lipoic acid products in individuals with a genetic variation which causes the body's own defence system to attack insulin (insulin autoimmune syndrome).

Organization: Health Canada | Santé Canada